AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06349122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal flora abnormalities screening and quantification using molecular biology technique
Description: Vaginal self-sampling is a simple and validated method of sampling used for the molecular biology technique and the quantification of microorganisms involved in vaginal flora imbalance bacteriosis.The patient performs a self-sampling with a cotton swab transferred into a transport medium tube. The sample is sent to the laboratory where Multiplex Point of Care polymerase chain reaction (PCR) is performed.
Study NCT06349122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycine
Description: In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)
Study NCT06349122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
Study NCT06205576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB catheter
Description: Trade name of DCB catheter：Acoart Orchid＆Dhalia
Study NCT06454071 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.
Study NCT06073444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus JP
Description: Picterus JP is a medical device consisting in a smartphone app which is use to take images of the skin of the newborn, a color calibration card that must be placed in the newborn chest to calibrate color and lighting in the images and a server to analyze data and estimate bilirubin level
Study NCT06107907 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)
Description: Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
Study NCT05798013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital health management
Description: The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.
Study NCT06138002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumbaCure®
Description: LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
Study NCT06138002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercises supervised by the physiotherapist
Description: A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
Study NCT05540041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bubble breathing play therapy group
Description: The efficacy of bubble breathing play therapy in the preoperative anxiety children and their parent.
Study NCT05540041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tell-show-do play therapy group
Description: The efficacy of tell-show-do play therapy in the preoperative anxiety children and their parent.
Study NCT05540041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Routine nursing care
Study NCT06649188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate Iontophoresis
Description: Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED) The phoresors II auto model PM850 IOMED allows the user to deliver a specific dose from 0 to 80 mA/min, control the current from 0 to 4 mA and automatically calculates required time for the selected dose. Current ramp-up and down, shut-off, error messages and safety checks are also performed automatically. The builtin option for manual current shut-off is an added safety feature (Teslim et al., 2013).~* Electrodes: Active-Anode (Drug Delivery).~* Drug Used: MgSO4 Aqueous Solution.~* Drug Ion Polarity: Positive Polarity.
Study NCT06649188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: Deep friction massage, stretching and pressure therapy.
Study NCT06649188 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional physical therapy program
Description: Deep friction massage, stretching and pressure therapy.
Study NCT06648109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Blanket
Description: Participants were randomized to groups A and B. When the subject\&#39;s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.
Study NCT06649461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ozone injections
Description: Ozone injections (5 mL/10 μg/dL) were administered under aseptic conditions, with the wrist fixed in dorsiflexion, and with the insulin injector, a 23-gauge needle was inserted between the palmaris longus and flexor carpi radialis muscles at a 45-degree angle from the palmar distal line (Salutem/19147884379).
Study NCT06649461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: hand splint for night
Study NCT06649461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: hand splint for night
Study NCT06373458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 50mg QD for 36 weeks starting at Day 1
Study NCT05725265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large-area low-level laser therapy(Venusure)
Description: The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
Study NCT05725265 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional low-level laser therapy
Description: The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
Study NCT04714788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECAP_MyLife mobile app
Description: The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention.
Study NCT04714788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual data collection methods
Description: Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
Study NCT05469763 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Circuit training
Description: Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week.
Study NCT05469763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training
Description: Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week.
Study NCT04699201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hincisional hernia prevention by onlay prosthesis trocar closure
Description: Hincisional hernia prevention by onlay prosthesis trocar closure
Study NCT04699201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with or without common bile duct exploration
Study NCT04699201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with or without common bile duct exploration
Study NCT06293014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102+bevacizumab
Description: TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.
Study NCT06293014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy+bevacizumab
Description: Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab
Study NCT04699201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal ultrasound
Description: Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
Study NCT04699201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Description: Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
Study NCT05739799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL
Description: Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
Study NCT05739799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode
Description: patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
Study NCT04530877 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
Study NCT04530877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition
Description: the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
Study NCT06337240 — intervention group
Intervention type: OTHER
Intervention: Pelvic floor on COPD patients
Description: Group A (study group) :~This group will include 30 COPD patients with urinary incontinence , who will receive pelvic floor exercise for 3 days a week for a total of 3 months.
Study NCT06337240 — intervention group
Intervention type: OTHER
Intervention: Pilates exercises on COPD patients
Description: Group B (study group):~This group will include 30 COPD patients with urinary incontinence , who will receive pilates for 3 days a week for a total 3 months.
Study NCT06262776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine adjuvanted (SHINGRIX)
Description: 2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
Study NCT05207631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic and standardised assessment of inhalers and implementation of a prescribing guide
Description: Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
Study NCT06344364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
Description: Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.
Study NCT05387681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: short course radiotherapy ：5\*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
Study NCT05041842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300 mg orally twice daily
Study NCT05041842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
Study NCT05041842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly
Study NCT05041842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Description: Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
Study NCT05041842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab/ Trastuzumab
Description: Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly
Study NCT05940129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women and Child, Safety, Health and Empowerment (WC-SHE)
Description: The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
Study NCT06197113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Rapid2 Magnetic Stimulator
Description: For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
Study NCT06197113 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Rapid2 Magnetic Stimulator
Description: For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
Study NCT05288387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
Study NCT06224335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running
Description: Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
Study NCT06128291 — intervention group
Intervention type: PROCEDURE
Intervention: posterior colporrhaphy
Description: posterior colporrhaphy for rectocele.
Study NCT06202625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: The avatrombopag 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase avatrombopag dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within avatrombopag dosage at 40 mg/d, decrease avatrombopag dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop avatrombopag; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping avatrombopag , reuse avatrombopag at 40 mg/d.
Study NCT06202625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
Study NCT06556277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone And Hydrocortisone
Description: Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7
Study NCT06556277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7
Study NCT06187961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
Study NCT06187961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus cadonilimab
Description: lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
Study NCT05220566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reserved Therapeutic Space
Description: The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
Study NCT05657613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP450 Cocktail and Transporter Substrates with Pacritinib
Description: Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg.